Vivanza Biosciences signs strategic cooperation agreement for Kyrgyz film project

1 min read     Updated on 29 Jun 2026, 03:29 PM
scanx
Reviewed by
Jubin VScanX News Team
AI Summary

Vivanza Biosciences Limited has entered into a Strategic Cooperation, Investment & Technology Transfer Agreement with Mr. Kalybek Uulu Bekturgan for a Plastic Film Manufacturing Project in the Kyrgyz Republic. The non-binding agreement encompasses technology transfer, investment facilitation, and potential joint venture formation. No monetary consideration was paid initially, and the company expects the move to enhance its international presence and export markets.

powered bylight_fuzz_icon
44272747

*this image is generated using AI for illustrative purposes only.

Vivanza Biosciences Limited has signed a Strategic Cooperation, Investment & Technology Transfer Agreement with Mr. Kalybek Uulu Bekturgan to establish a Plastic Film Manufacturing Project in the Kyrgyz Republic. The international agreement aims to strengthen the company's presence in the region through industrial cooperation and technology transfer. No monetary consideration was exchanged at the signing of this non-binding pact.

The agreement outlines a scope of work that includes technology transfer, project design and implementation support, machinery sourcing, and government liaison. It also provides for investment facilitation, skill development, import-export promotion, and financing assistance. The parties may explore the possibility of establishing a Joint Venture Company, subject to the execution of definitive agreements and necessary approvals.

Key Agreement Details

Particulars Details
Name of Entity Vivanza Biosciences Limited and Mr. Kalybek Uulu Bekturgan
Area of Agreement Strategic cooperation for establishment of Plastic Film Manufacturing Project
Location Kyrgyz Republic
Consideration No monetary consideration at present
Related Party Transaction Not Applicable (N.A.)

The company expects the arrangement to facilitate international industrial cooperation and expand export markets. While the agreement is intended to create long-term growth opportunities, the company noted that no immediate financial benefit can be quantified due to the non-binding nature of the pact. Vivanza Biosciences will disclose any termination of the arrangement to the stock exchange in accordance with SEBI regulations.

Historical Stock Returns for Vivanza Biosciences

1 Day5 Days1 Month6 Months1 Year5 Years
-1.50%+11.30%+11.30%-5.29%-7.08%-82.87%

What is the projected timeline for executing definitive agreements and establishing the Joint Venture Company?

How will Vivanza Biosciences secure the necessary financing for the project given no monetary consideration was exchanged upfront?

What specific regulatory approvals from the Kyrgyz Republic government are required before operations can commence?

Vivanza Biosciences appoints Hemant Amrish Parikh as director

0 min read     Updated on 18 Jun 2026, 02:15 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Vivanza Biosciences Limited announced the appointment of Mr. Hemant Amrish Parikh as an Additional Non-Executive Non-Independent Director for a term of five years effective June 18, 2026, pending shareholder approval. Concurrently, the Board appointed M/s. Dharti Shah & Co. as the Internal Auditor for the financial year 2026-2027.

powered bylight_fuzz_icon
43050218

*this image is generated using AI for illustrative purposes only.

Vivanza Biosciences Limited has appointed Mr. Hemant Amrish Parikh as an Additional Non-Executive Non-Independent Director effective June 18, 2026. The appointment is for a period of five years, subject to the approval of shareholders in the upcoming General Meeting. Mr. Parikh is a Chemical Engineer with over 30 years of experience in the pharmaceutical industry and currently serves as the Managing Director of Vivanta Industries Limited.

The Board meeting, held on June 18, 2026, also approved the appointment of M/s. Dharti Shah & Co. as the Internal Auditor for the Financial Year 2026-2027. Ms. Dharti Shah, a qualified Chartered Accountant, holds a certificate of practice since April 7, 2017. The firm's registration number is 144870W.

Board Meeting Outcomes

Agenda Item Details
Director Appointment Mr. Hemant Amrish Parikh as Non-Executive Non-Independent Director for 5 years
Internal Auditor M/s. Dharti Shah & Co. appointed for FY27
Meeting Duration Commenced at 13:30 P.M. and concluded at 14:00 P.M.

Historical Stock Returns for Vivanza Biosciences

1 Day5 Days1 Month6 Months1 Year5 Years
-1.50%+11.30%+11.30%-5.29%-7.08%-82.87%

How will Mr. Parikh's extensive pharmaceutical experience influence Vivanza Biosciences' strategic direction over the next five years?

What synergies can be expected between Vivanza Biosciences and Vivanta Industries given Mr. Parikh's leadership role in both companies?

Will the appointment of a new internal auditor lead to changes in the company's financial reporting or compliance practices?

More News on Vivanza Biosciences

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:-7.08%